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Abstract 
Calmodulin (CAM) is a mzjor intracellular calcium binding protein which has been implicated in the regulation of cell proliferation. 
Previous studies using chemically synthesized CaM antagonists and anti-sense RNA indicated that CaM is important for initiation of 
DNA synthesis and cell cycle progression. However, these methods reduce total intracellular CaM and globally interfering with all the 
CaM-dependent processes. In order to explore the function of nuclear CaM during the cell cycle, a CaM inhibitor peptide was targeted to 
the nucleus of intact mammalian cells. Cell progression through S-phase was assessed by incorporation of the thymidine analogue, BrdU. 
Cells were transfected for 48 h with either the CaM inhibitor peptide gene or the control plasmid prior to analysis. Approx. 70% of the 
control cells incorporated BrdU. In striking contrast, double immunofluorescent labeling demonstrated that none of the cells expressing 
the CaM inhibitor peptide entered S-phase. This result indicates that neutralization of nuclear CaM by targeted expression of a CaM 
inhibitor peptide blocks DNA synthesis and cell cycle progression. 
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1. Introduction 
Calmodulin (CAM) is a major intracellular calcium 
binding protein [1]. CaM mediates the Ca 2+ signal through 
direct interactions with its target proteins. A common 
feature of CaM binding proteins is that they contain an 
endogenous autoregulatory domain [2]. This domain is 
composed of a pseudosub~trate region which overlaps the 
CaM binding site of the enzyme. When intracellular Ca 2+ 
is at resting levels, the pseudosubstrate region binds to the 
catalytic site of the enzyme, suppressing activity. Transient 
increases of intracellular f ee Ca 2+ cause CaM to undergo 
a conformational change; Ca2+/CaM then binds its target 
site on the enzyme, dislocating the autoinhibitory domain 
and thereby activating the enzyme (for review, see Ref. 
[3]). The CaM binding sites of target enzymes are ideal 
CaM inhibitors. 
CaM has been suggested to be involved in the regula- 
tion of cell proliferation [4,5]. Chafouleas et al. [6] reported 
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that total cellular CaM increases at late G1 in CHO-K1 
cells. Rasmussen and Means [7] found that constitutive 
elevation of intracellular CaM levels shortened the cell 
cycle time mainly by reducing the G1 phase. In contrast, 
CaM antagonist studies, such as W7 and W13, demon- 
strated that the cell cycle was blocked at the G1/S  bound- 
ary, and DNA synthesis was inhibited [6,8]. The major 
disadvantage of these pharmacological agents is their non- 
specificity. These hydrophobic ompounds interact with 
other intracellular proteins, such as protein kinase C, onco- 
modulin, troponin C, and membrane receptors, in addition 
to CaM [9]. Rasmussen and Means [10] found that tran- 
sient expression of CaM anti-sense RNA in mouse C127 
cells caused a temporary cell cycle arrest at G1. Reddy et 
al. [11] reported that DNA synthesis was blocked when 
monoclonal antibody against CaM was applied to perme- 
abilized CHO cells. In these studies, the total cellular CaM 
level was altered and all CaM-dependent processes were 
affected. 
Regulation of cell growth and proliferation is a complex 
process involving signalling between the plasma mem- 
brane, nuclear and cytoplasm. Many cell cycle regulatory 
events, such as DNA synthesis, occur in the nucleus. CaM 
has been shown to be a dynamic component of this 
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organelle. Gough and Taylor [12] reported that the concen- 
tration of CaM can be significantly higher in the nucleus 
than in the cytosol. In addition, Pruschy et al. [13] found 
that CaM does not freely diffuse into the nucleus; it is 
imported via a facilitated transport mechanism. The precise 
role of CaM in regulating nuclear functions remains unde- 
fined. In order to explore the function of nuclear CaM 
during the cell cycle, a potent CaM inhibitor peptide 
containing nuclear localization sequences was expressed to 
specifically neutralize nuclear CaM. 
(CaMBP) 4 [14] was transiently transfected into COS-7 
cells using a modified calcium precipitation method [15]. 
Recombinant DNA (30 txg) was mixed with 0.25 M 
CaC12, precipitated with BES buffer (pH 6.95), and evenly 
added to COS cells plated at a concentration of 5 × 104 
cells/ml. After 20 h of incubation, cells were washed with 
PBS and fresh medium was added. Parental plasmid pSVL 
was used as the control. 
2.2. Immunostaining 
2. Materials and methods 
2.1. Cell culture and transfection 
COS-7 cells were maintained in Dulbecco's modified 
Eagle's medium (Life Technologies Inc.) containing 10% 
fetal bovine serum at 37°C in a 5% CO 2 humidified 
incubator. The mammalian expression construct pSVL- 
Transfected cells were grown on 22 × 22 mm cover- 
slips. At 47 h after transfection, cells reached approx. 60% 
confluency and were incubated with 5-bromo-2'-deoxy- 
uridine (BrdU) labeling medium with the final concentra- 
tion of 10 txmol/1 BrdU (Boehringer Mannheim Co.) for 1 
h. Cells on coverslips were washed in PBS and fixed in 
70% ethanol (in 50 mmol/1 glycine buffer, pH 2.0) for 20 
min at -20°C. Fixed cells were incubated with mono- 
clonal antibody against BrdU at 37°C for 30 min, washed 
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Fig. 1. Design and construction of calmodulin inhibitor peptide concatemer genes. (A) Two 72 bp oligonucleotides coding for the skMLCK CaM binding 
site and its complimentary sequence, ach containing XmaI restriction enzyme overhangs, were synthesized in the DNA Core Facility at University of 
Cincinnati. Equimolar amounts of each synthetic oligonucleotide (1 Izg) were annealed by denaturing at 95°C for 5 min followed by slow cooling to room 
temperature. The double-stranded XmaI-XmaI fragment was cloned into the XmaI site of vector pBluescript SK II (Stratagene) using T4 DNA ligase 
(USB). The appropriate orientation and sequence of the synthetic peptide gene (CaMBP) was confirmed by Sanger's dideoxy DNA sequencing method 
(USB). Two primers, (upstream 5'-CGTACTCGGGATGAAGAGAAGATGG-3' and downstream 5'-ACTACCCGAGCTTCTTGAATCTGTr-3') were 
used to introduce an AvaI restriction enzyme site (underlined) at each end of the cloned CaMBP monomer gene. Polymerase chain reaction (PCR) was 
performed at 94°C for 30 s, 57°C for 30 s and 72°C for 1 min for 30 cycles (Thermolyne) using Vent polymerase (NEB). (B) PCR products (10 txg) were 
purified by phenol/chloroform extraction, digested with AvaI restriction enzyme and self-ligated at 16°C overnight using T4 DNA ligase (USB). The 
ligation mixture was analyzed in a 2% agarose gel. 
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and treated with fluorescein.-conjugated sheep anti-mouse- 
IgG. Cells were then immunostained with affinity-purified 
rabbit-anti-MLCK peptide antibody [14] visualized with 
CY3-conjugated goat anti-rabbit IgG (Jackson Laborato- 
ries). The coverslips were then mounted and photographed 
using Kodak Elite 200 Ektachrome film with a Nikon 
Microflex UFX exposure attachment mounted on a Nikon 
Optiphot epifluorescence microscope with the appropriate 
Nikon fluorescence filter cubes. 
3. Results and discussion 
The CaM binding region of rabbit skeletal muscle 
myosin light chain kinase (skMLCK) was selected to be 
expressed as a specific CaM inhibitor. This 19 amino acid 
peptide has a high binding affinity for calmodulin (K d = 1 
nM) [16]. In vitro studies have shown that the synthetic 
MLCK peptide binds CaM in a Ca2+-dependent manner 
and is a competitive inhibitor of several CaM-dependent 
enzymes [17]. A 72 base pair synthetic gene encoding the 
19 amino acid skMLCK calmodulin binding site was 
designed and synthesized (Fig. 1A). This synthetic gene 
contained the XmaI restriction enzyme site 'CCCGGG' to 
facilitate cloning into pBluescript SK. 
The CaM binding peptide gene was constructed as 
tandem repeats for several reasons. First, since CaM is an 
abundant protein in cells, it was important to maximize the 
CaM binding capacity of each transcript. Second, cells do 
not utilize small genes; larger precursors are synthesized 
and processed post-translationally. In addition, small pep- 
tides are unstable in the cytosol [18]. The multiple joined 
segments of the CaM binding peptide would prevent pro- 
tein product degradation. Finally, tandem repeats of the 
CaM binding peptide create several nuclear localization 
signals, ensuring that the inhibitor peptide is properly 
targeted and concentrated within the nucleus. 
The strategy used to construct he concatemer genes 
included PCR amplification to incorporate AvaI restriction 
enzyme sites (CTCGGG) at the ends of each monomer 
gene (Fig. 1A). Following AvaI digestion, the 66 bp 
monomer gene self-ligated into head-to-tail tandem re- 
peats. This procedure produced a complex mixture of 
concatemers anging from 2 to more than 40 monomer 
units (Fig. 1B). The ligation mixture was blunt-ended and 
cloned into the SmaI site of pBluescript SK. Clones con- 
taining 2, 3, 4, 6, 8, and i~4 repeats of the CaM binding 
peptide gene were characterized (Fig. 2). 
We elected to use a four-repeat concatemer gene since 
the protein product would be approx. 12 kDa and would 
contain multiple nuclear localization signals (NLS), includ- 
ing K-K/R-X-K/R and the KK . . . . . .  KK bipartite motif 
(Fig. 3A). Many nuclear proteins such as the SV40 T 
antigen, DNA polymerase ,a and transcription factors con- 
tain such consensus sequences for nuclear targeting [19,20]. 
The amino acids Leu, Gly, and Met, act as a spacer 
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Fig. 2. Electrophorestic analysis of cloned concatemer calmodulin in- 
hibitor peptide genes. The self-ligated concatemer mixture was blunt- 
ended using Klenow enzyme (Life Technologies Inc.) and cloned into the 
Sinai site of pBluescript SK. Recombinant DNA was transformed into 
XLI-Blue competent cells (Stratagene). The cloned genes were released 
from the vector by NotI and EcoRI digestion and separated on a 2% 
agarose gel. Concatemer genes containing 2, 3, 4, 6, 8, and 14 repeats 
were cloned. 
between each CaM binding unit. The concatemer CaM 
inhibitor peptide is capable of binding multiple CaM 
molecules, thus preventing activation of CaM target pro- 
teins in the nucleus (Fig. 3B,C). 
Wang et al. [14] found that expression of this CaM 
inhibitor peptide caused the formation of irregular nuclei. 
The cell cycle check point that was blocked by the CaM 
inhibitor peptide was not determined. Incorporation of 
BrdU, a thymidine analogue, into DNA is an indicator of 
DNA synthesis. This activity during the S-phase of the cell 
cycle is required for cell proliferation. COS-7 cells were 
transfected with the recombinant concatemer (CaMBP) 4 
gene (Fig. 4A). After 48 h, cells were pulsed with BrdU 
for 1 h, fixed and immunostained with monoclonal anti- 
BrdU antibody to determine progression i to the S-phase. 
Immunostaining with affinity-purified anti-MLCK peptide 
antibody indicated that approx. 40-50% of the cells were 
transfected with recombinant (CaMBP) 4 (Fig. 4B). Ex- 
pressed CaM inhibitor peptides were localized within the 
nucleus, Double immunostaining of transfected cells indi- 
cated that cells which expressed the CaM inhibitor peptide 
did not incorporate BrdU (Fig. 4C,D). In contrast, approx. 
70% of cells transfected with a control plasmid incorpo- 
rated BrdU (Fig. 4E). These results demonstrated that 
DNA synthesis did not occur in cells which expressed the 
CaM inhibitor peptide. 
Neutralization of nuclear CaM with a CaM binding 
peptide prevented DNA synthesis. This result indicates that 
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Fig. 3. Neutralization of nuclear calmodulin by targeted expression of calmodulin inhibitor peptide. (A) The derived amino acid sequence of the four repeat 
CaM inhibitor peptide gene contains multiple nuclear localization signals (underlined). (B) Activation of a Ca2+/CaM-dependent binding protein. (C) 
Inactivation of a Ca2+/CaM target protein by neutralization of CaM function with CaM inhibitor peptide. 
nuclear CaM plays an important role in progression of the 
cell cycle into S-phase. The activity of DNA polymerase 
e~, which is critical in DNA replication, has been reported 
to be inhibited by the CaM antagonists WI3 and TFP, thus 
blocking the cell cycle at G1/S boundary of NRK cells 
[21]. The membrane permeable CaM kinase II inhibitor, 
KN-93, arrested Hela cells and NIH 3T3 cells at G1/S 
[22,23]. None of the DNA replicative nzymes, however, 
have been shown to be directly regulated by Ca2+/CaM. 
A dominant-negative strategy to design peptides which 
inhibit target proteins within specific cellular compart- 
ments allows for molecular dissection of cellular function. 
We have applied this approach to evaluate the role of 
nuclear CaM during the cell cycle. Selective inhibition of 
individual CaM target enzymes will further delineate the 
mechanism of cell cycle regulation. 
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monoclonal antibody against BrdU, visualized by fluorescein-conjugated sheep anti-mouse IgG (C). (B) and (C) are the same field (20 × ). (D) Double 
exposure of double-immunostained transfected cells at high magnification (60 X ). (E) COS-7 cells transfected with parental plasmid pSVL. BrdU 
incorporation was detected with she same method as (C) (20 × ). 
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